3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Leukemia, Myeloid, Acute
6
Neoplasm Metastasis
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Lung Neoplasms
3
Endometrial Neoplasms
3
Congenital Abnormalities
3
Colonic Neoplasms
3
Breast Neoplasms
3
Sarcoma
2
Oropharyngeal Neoplasms
2
Neuroblastoma
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Leukemia
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Anus Neoplasms
2
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Interventions
Cyclophosphamide
3
Epirubicin
2
Docetaxel
2
Carboplatin
2
Capecitabine
2
Azacitidine
2
venetoclax
1
tegafur-gimeracil-oteracil
1
taxane
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pirarubicin
1
pertuzumab
1
pembrolizumab
1
olaparib
1
cc-486
1
Trastuzumab
1
Thalidomide
1
Radiotherapy
1
Radiation
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Methotrexate
1
Magnetic Resonance Imaging
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pathologic Complete Response
×
Observation
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled